Vessel dilator and kaliuretic hormone, two cardiovascular peptide hormones, enhance urine flow 2- to 13-fold and 4-fold, respectively, in persons with class III New York Heart Association congestive heart failure (CHF). The natriuresis and diuresis secondary to vessel dilator and kaliuretic hormone are not blunted as are atrial natriuretic peptide and brain natriuretic peptide effects in persons with CHF compared with healthy individuals. The present investigation determined if the two peptide hormones that do not have blunted effects in persons with CHF may have added beneficial effects when given simultaneously to individuals with class III CHF. Together with each at 100 ng/kg of body weight per minute, vessel dilator and kaliuretic hormone increased urine flow rate 3.5-fold (P < 0.05) compared with their 60-min baseline and control CHF subjects' urine flow rates. Combined, they enhanced the excretion rate of sodium a maximum of 3.6-fold (P < 0.05) with 2.5- and 2-fold enhancement 2 and 3 hrs after infusion. These data indicate that vessel dilator and kaliuretic hormone have diuretic and natriuretic effects when used in combination, but these effects are not additive over their individual effects in persons with CHF.
VeselyDL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life53: 153–159, 2002.
3.
WintersCJ, SallmanAL, BakerBJ, MeadowsJ, RicoDM, VeselyDL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation80: 438–449, 1989.
4.
HunterEFM, KellyPA, ProwseC, WoodsRJ, LowryPJ. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scand J Clin Lab Invest58: 205–216, 1998.
5.
DaggubatiS, ParksJR, OvertonRM, CintronG, SchockenDD, VeselyDL. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res36: 246–255, 1997.
6.
MartinDR, PevahouseJB, TriggDJ, VeselyDL, BuerkertJE. Three peptides from the ANF prohormone NH2-terminus are natriuretic and/or kaliuretic. Am J Physiol258: F1401–F1408, 1990.
7.
GunningME, BradyHR, OtuechereG, BrennerBM, ZiedelML. Atrial natriuretic peptide (31-67) inhibits Na+ transport in rabbit inner medullary collecting duct cells: role of prostaglandin E2. J Clin Invest89: 1411–1417, 1992.
8.
VillarrealD, ReamsGP, TarabenA, FreemanRH. Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med221: 166–170, 1999.
9.
VeselyDL, DouglassMA, DietzJR, GowerWRJr, McCormickMT, Rodriguez-PazG, SchockenDD. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce a diuresis, natriuresis, and/or kaliuresis in humans. Circulation90: 1129–1140, 1994.
10.
VeselyDL, DietzJR, ParksJR, BaigM, McCormickMT, CintronG, SchockenDD. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation98: 323–329, 1998.
11.
NasserA, DietzJR, SiddiqueM, PatelH, KhanN, AntwiEK, San MiguelGI, McCormickMT, SchockenDD, VeselyDL. Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. Am J Cardiol88: 23–29, 2001.
12.
CodyRJ, AtlasSA, LaraghJH, KuboSH, CovitAB, RymanKS, ShaknovichA, PondolfinoK, ClarkM, CamargoMJF, ScarboroughRM, LewickiJA. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest78: 1362–1374, 1986.
13.
VeselyDL, DietzJR, ParksJR, AntwiEA, OvertonRM, McCormickMT, CintronG, SchockenDD. Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J138: 625–632, 1999.
14.
AbrahamWT, LowesBD, FergusonDA, OdomJ, KimJK, RobertsonAD, BristowMR, SchrierRW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Cardiac Fail4: 37–44, 1998.
15.
MillsRM, LeJemtelTH, HortonDP, LiangCS, LangR, SilverMA, LuiC, ChatterjeeK. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure. J Am Coll Cardiol34: 155–162, 1999.
16.
JensenKT, EiskjaerH, CarstensJ, PedersenEB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci96: 5–15, 1999.
17.
BenjaminBA, PetersonTV. Effect of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol269: R1351–R1355, 1995.
18.
WintersCJ, SallmanAL, MeadowsJ, RicoDM, VeselyDL. Two new hormones: prohormone atrial natriuretic peptides 1-30 and 31-67 circulate in man. Biochem Biophys Res Commun150: 231–236, 1988.
19.
WintersCJ, VeselyDL. Change in plasma immunoreactive N-terminus, C-terminus, and 4000 dalton mid portion of atrial natriuretic factor prohormone with hemodialysis. Nephron58: 17–22, 1991.
20.
VeselyDL, PrestonR, WintersCJ, RicoDM, SallmanAL, EpsteinM. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in cirrhotic humans. Am J Nephrol11: 207–216, 1991.
21.
VeselyDL, PrestonR, GowerWRJr, ChiouS, EpsteinM. Increased release of kaliuretic peptide during immersion-induced central hypervolemia in cirrhotic humans. Am J Nephrol16: 128–137, 1996.
22.
ChiouS, VeselyDL. Kaliuretic peptide. The most potent inhibitor of Na+-K+-ATPase of the atrial natriuretic peptides. Endocrinology136: 2033–2039, 1995.
VeselyDL, San MiguelGI, HassanI, SchockenDD. Intact negative feedback of four cardiac hormones in congestive heart failure. Metabolism51: 582–588, 2002.
25.
VeselyDL, ChiouS, DouglassMA, McCormickMT, Rodriguez-PazG, SchockenDD. Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. J Endocrinol146: 373–380, 1995.
26.
VillarrealD, FreemanRH, TarabenA, ReamsGP. Modulation of renin secretion by atrial natriuretic factor prohormone fragment 31-67. Am J Med Sci18: 330–335, 1999.
